Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients

Nephrology Dialysis Transplantation

Volumn 23, Issue 1, 2008, Pages 328-335

  Fukagawa, Masafumi ^a   Yumita, Shigeru ^b   Akizawa, Tadao ^c   Uchida, Eiji ^c   Tsukamoto, Yusuke ^d   Iwasaki, Manabu ^e   Koshikawa, Shozo ^f  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kojinkai Central Clinic   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Kasukabe Shuwa Hospital   (Japan)

^e SEIKEI UNIVERSITY   (Japan)

^f SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Calcimimetics; Calcium; Calcium sensing receptor; Cinacalcet; Phosphorus; PTH; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; CALCIUM CARBONATE; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; VITAMIN D; NAPHTHALENE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPOCALCEMIA; JAPANESE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; STOMACH DISCOMFORT; VOMITING; BLOOD; HYPERPARATHYROIDISM; JAPAN; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

CALCIUM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPARATHYROIDISM; JAPAN; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS;

EID: 44449098194     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm534     Document Type: Article

References (25)

1. Torres A, Lorenzo V, Hernandez D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442
2. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999; 56 [Suppl 73]: S14-S19
3. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
4. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
5. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int 2005; 67: 1179-1187
6. Coburn JW. An update on vitamin D as related to nephrology practice: 2003. Kidney Int 2003; 64 [Suppl 87]: S125-S130
7. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 [Suppl 3]: S1-S201
8. Goodkin D, Brragg-Gresham J, Koenig K et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 10: 3270-3277
9. 2+-receptor-mediated regulation of parathyroid and renal function. Am J Med Sci 1996; 312: 99-109
10. Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004; 308: 627-635
11. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
12. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807
13. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248-254
14. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583
15. Payne RB, Little AJ, Williams RB et al. Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J 1973; 4: 643-646
16. Tominaga Y, Matsuoka S, Sato T et al. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxiacalcitol treatment and required parathyroidectomy. Ther Apher Dial 2007; 11: 269-276
17. Nakai S, Wada A, Kitaoka T et al. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial 2006; 10: 476-497
18. Arenas M, Alvarez-Ude F, Gill M et al. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007; 1-6
19. Kruse AE, Eisenberger U, Frey FJ et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1311-1314
20. Serra AL, Schwarz AA, Wick FH et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1315-1319
21. Apostolou T, Damianou L, Kotsiev V et al. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clin Nephrol 2006; 65: 374-377
22. Ohashi N, Uematsu T, Nagashima S et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharm 2003; 57: 726-734
23. Harris RZ, Padhi D, Marbury TC et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200mg once daily. Am J Kidney Dis 2004; 44: 1070-1076
24. Yokoyama K, Shigematsu T, Tsukada T et al. Calcium-sensing receptor gene polymorphism affects the parathyroid response to moderate hypercalcemic suppression in patients with end-stage renal disease. Clin Nephrol 2002; 57: 131-135
25. Hansjorg M, Rothe HM, Shapiro WB et al. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogenet Genomics 2005; 15: 29-34